ArticleUrology2026
Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria.
Article in Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.Future science OA · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate the performance the Hematuria Cancer Risk Score (HCRS) in combination with the urine-based biomarker test Oncuria-Detect for the detection of bladder cancer in a cohort of patients referred for hematuria evaluation.
methodsA cohort of 365 patients undergoing microscopic and gross hematuria evaluation were prospectively recruited to provide voided urine samples and pertinent clinical information. Then, retrospectively the primary outcome of sensitivity, specificity, and area under the curve (AUC) for HRCS and Oncuria for bladder cancer detection were reported.
resultsOf the final cohort, 55 patients were diagnosed with bladder cancer and 310 served as controls. In this cohort, HCRS alone achieved a sensitivity of 90.9%, specificity of 71.9% with an AUC of 0.890 (95%CI: 0.832-0.948) and NPV of 0.978. Oncuria achieved a comparable performance with sensitivity of 78.2%, specificity of 76.8%, and an AUC of 0.838 (95%CI: 0.770-0.906) with NPV of 0.949. Evaluation using the HCRS and Oncuria in combination produced a sensitivity of 87.3% and specificity of 80.6%. The combined approach had an AUC of 0.909 (95%CI: 0.855-0.962) and NPV of 0.973. For patients with microhematuria, HCRS and Oncuria together yielded a sensitivity of 82.4% and a negative predictive value of 98.7%.
conclusionThe HCRS achieves strong predictive power for the detection of bladder cancer in patients undergoing hematuria work up. The addition of the Oncuria-Detect test provides incremental improvement to this performance. Both tests can be performed at the initial primary care encounter for hematuria and may improve patient selection for cystoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.